AU Patent

AU2020202029A1 — Nasal Administration

Assigned to Optinose AS · Expires 2020-04-09 · 6y expired

What this patent protects

NASAL ADMINISTRATION An apparatus for or method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for ex…

USPTO Abstract

NASAL ADMINISTRATION An apparatus for or method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for example, chronic rhinosinusitis, optionally with polyps, the method comprising the steps of fitting a nosepiece to one nostril of the subject, delivering the substance through the nosepiece to the posterior region of the nasal cavity of the subject. 134 WO 2015/197798 PCT/EP2015/064463 4/41 53 - - 17 c 77 -16 19 20f ~65 7 79 15 F1IG. 2 (b)

Drugs covered by this patent

Patent Metadata

Patent number
AU2020202029A1
Jurisdiction
AU
Classification
—
Expires
2020-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Optinose AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.